Art

J-GLOBAL ID：201402282439003135   Reference number：14A1330176

Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial

メトトレキサートに不十分な応答の日本人関節リウマチ患者におけるセルトリズマブペゴール+メトトレキサートの有効性と安全性 J-RAPIDランダム化プラセボ比較試験

Author (13)： YAMAMOTO Kazuhiko (Univ. Tokyo, Tokyo, JPN) ,  TAKEUCHI Tsutomu (Keio Univ. School of Medicine, Tokyo, JPN) ,  YAMANAKA Hisashi (Tokyo Women’s Medical Univ., Tokyo, JPN) ,  ISHIGURO Naoki (Nagoya Univ. Graduate School, Aichi, JPN) ,  TANAKA Yoshiya (Univ. Occupational and Environmental Health, Fukuoka, JPN) ,  EGUCHI Katsumi (Sasebo City General Hospital, Nagasaki, JPN) ,  WATANABE Akira (Tohoku Univ., Miyagi, JPN) ,  ORIGASA Hideki (Univ. Toyama School of Medicine, Toyama, JPN) ,  SHOJI Toshiharu (Otsuka Pharmaceutical Co., Ltd., Tokyo, JPN) ,  SAKAMAKI Yoshiharu (UCB Japan, Tokyo, JPN) ,  VAN DER HEIJDE Desiree (Leiden Univ. Medical Centre, Leiden, NLD) ,  MIYASAKA Nobuyuki (Tokyo Medical and Dental Univ., Tokyo, JPN) ,  KOIKE Takao (Hokkaido Univ. Graduate School of Medicine, Hokkaido, JPN)
Material： Modern Rheumatology  (Mod Rheumatol)
Volume： 24  Issue： 5  Page： 715-724  Publication year： Sep. 2014 
JST Material Number： L5142A  ISSN： 1439-7595  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： RCT ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=14A1330176&from=J-GLOBAL&jstjournalNo=L5142A") }}

JST classification (2)： Clinical application of anti-inflammatory drugs  (GW15020E) ,  Drug therapy(=pharmacotherapy)for musculoskeletal diseases  (GG05020D)

Substance index (1)： Methotrexate

Reference (24)：

• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932-9.
• Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340(4):253-9.
• Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35-45.
• Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50(4):1051-65.
• Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797-804.

Terms in the title (12)： メトトレキサート ,  応答 ,  日本人 ,  関節リウマチ ,  患者 ,  セルトリズマブペゴール ,  有効性 ,  安全性 ,  RaPID ,  ランダム化 ,  プラセボ ,  比較試験